Adjusted for:
Global supply chain
initiative(1) 4,740 - 23,904 -
Acquisition and licensing
charges 1,000 1,710 6,500 11,288
Gain on sale of assets (8,250) (10,617) (9,605) (13,089)
Loss on asset sales and
impairments 303 4,499 303 4,499
Favorable settlement of tax
related liability (5,928) - (5,928) -
Loss on debt repurchases - - 1,095 4,410
Legal settlements - 8,500 (15,000) 8,658
Income taxes (9,000) (1,534) (12,673) (6,012)
Adjusted net income 53,926 37,164 170,589 112,381
Add: Interest expense on CODES,
net of tax 1,979 1,905 5,910 5,906
Adjusted net income, adjusted for
interest on CODES $55,905 $39,069 $176,499 $118,287
Diluted earnings per share
Diluted earnings per
share - GAAP $0.62 $0.31 $1.60 $0.93
Diluted earnings per
share - Adjusted $0.47 $0.33 $1.50 $1.01
Basic weighted average common
shares outstanding 102,893 102,453 102,749 102,266
Effect of dilutive securities:
Conversion of CODES 14,357 14,357 14,357 14,357
Dilutive share-based
compensation arrangements 745 611 555 419
Diluted weighted average common
shares outstanding 117,995 117,421 117,661 117,042
(1) Includes accelerated depreciation charges of $1,807 and $5,600,
respectively.
The fol
'/>"/>
| SOURCE Watson Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |